Investors & Media
Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam
Company’s Resources Focused on Advancement of All Key Pipeline Programs
“With today’s announcement of a settlement with Alnylam, we are now able
to focus the entirety of our resources on the advancement of our key
clinical and discovery programs,” said
Under terms of the agreement, Alnylam will dismiss all claims of trade
secret misappropriation and other related claims brought in the
Massachusetts State Court against Dicerna. In return, Dicerna will
dismiss all counterclaims associated with Alnylam’s trade secret
misappropriation litigation, as well as all claims of anti-competitive
practices brought by Dicerna against Alnylam in Massachusetts Federal
Court. Dicerna will pay to Alnylam an upfront fee of
Neither company admits wrongdoing.
With the strength of its intellectual property affirmed, Dicerna remains focused on its core research and development activities, including its ongoing Phase 1 trial of DCR-PHXC, its lead compound for the treatment of all forms of primary hyperoxaluria, as well as the expected advancement of multiple other GalXC-based programs, including DCR-HBVS for hepatitis B, into clinical development on schedule. The company continues to anticipate having a total of three GalXC product candidates in the clinic by early next year.
Dicerna continues to actively progress development activities for its three priority GalXC programs:
- DCR-PHXC, an investigational treatment for all forms of primary hyperoxaluria, is currently in Phase 1 clinical trials with proof-of-concept data expected in the second half of 2018.
- DCR-HBVS, an investigational treatment for chronic hepatitis B virus, is in pre-clinical development and the Company anticipates filing an investigational new drug (IND) application or clinical trial application (CTA) during the fourth quarter of 2018.
- An undisclosed rare disease program, which the Company intends to advance into clinical trials in conjunction with a partner, with an anticipated IND or CTA filing in the second half of 2018.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statements. Examples of forward-looking statements
include, among others, statements we make regarding: (i) the therapeutic
and commercial potential of GalXC™; (ii) research and development plans
related to GalXC; (iii) the potential of our technology and drug
candidates in our research and development pipeline; and (iv) the timing